Pressure-Enabled Drug Delivery (PEDD™) of a Class C TLR9 Agonist in Combination with Checkpoint Inhibitor Therapy in a Murine Pancreatic Cancer Model
… Enhanced Delivery of a TLR9 Type C Agonist SD-101 to Liver Tumors in the Oncopig using Pressure Enabled Drug Delivery (PEDD™) Versus a Standard Endhole Catheter
… Improved Delivery of a TLR-9 Agonist to Liver Tissue by Intravascular Pressure-Enabled Drug Delivery (PEDD™) Compared with Direct Needle Injection
… Regional Infusion of a Class C TLR9 Agonist Enhances Liver Tumor Microenvironment Reprogramming and MDSC Reduction to Improve Responsiveness to Systemic Checkpoint Inhibition
… Comparison of Pancreatic Tissue Uptake of Oxaliplatin Delivered by Systemic Circulation and by Pancreatic Retrograde Venous Infusion (PRVI)
… Abstract No. 158628: PERIO-01: Enabling Tumor Microenvironment Reprogramming by a TLR9 Agonist Using Pressure-Enabled Drug Delivery™ (PEDD™) to Address Intrahepatic Immunosuppression and Drug Delivery Barriers
… Antireflux Catheter Improves Tumor Targeting in Liver Radioembolization with Resin Microspheres
… Abstract No. 1793: Regional Administration of Class C CpG Oligodeoxynucleotides Results in Superior Intrahepatic TLR9 Activation and Immunomodulation Compared to Systemic Infusion
… HITM-SURE: Hepatic Immunotherapy for Metastases Phase Ib Anti-CEA CAR-T Study Utilizing Pressure-Enabled Drug Delivery (PEDD™)
… Abstract No. 9534: Phase 1b/2, Open Label, Multicenter, Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced Melanoma Who Are Naïve to Anti-PD-1/L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870)
…